Skip to main content
Journal of Experimental & Clinical Cancer Research : CR logoLink to Journal of Experimental & Clinical Cancer Research : CR
. 2019 Jan 24;38:34. doi: 10.1186/s13046-019-1022-5

Correction to: EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways

Cheng Lin 1,2, Jingfeng Zong 2, Wansong Lin 3, Minghui Wang 4, Yuanji Xu 2, Rui Zhou 1, Shaojun Lin 2, Qiaojuan Guo 2, Honglin Chen 5, Yunbin Ye 3,6, Bin Zhang 4,✉, Jianji Pan 2,✉
PMCID: PMC6346539  PMID: 30678708

Correction to: Journal of Experimental & Clinical Cancer Research (2018) 37:283.

Doi 10.1186/s13046-018-0953-6

Following publication of the original article [1], the authors reported two errors in the article.

  • In the caption of Fig. 1c the sentence “The 20 most highly upregulated EBV BART miRNAs identified between NPC specimens and normal nasopharyngeal mucosal specimens” should instead read “The highly upregulated EBV BART miRNAs identified between NPC specimens and normal nasopharyngeal mucosal specimens”.

  • In Fig. 3a, the first image in the BART8-3p group was inadvertently imported and replaced with the original one in the NC group. A corrected version of Fig. 3 is shown in this Correction.

Fig. 3.

Fig. 3

Overexpression of EBV-miR-BART8-3p promotes lung metastasis of NPC in vivo. a Nude mice were intravenously injected with SUNE-1-BART8-3p cells or control vector-transfected SUNE-1 cells via the tail veins, and were sacrificed 6 weeks post-injection. Representative images in vivo were obtained by the whole-body imaging system. b Representative images of metastatic nodules in mouse lungs. c Number of metastatic nodules in mouse lungs. d Weight of mouse lungs. *P < 0.05

Contributor Information

Bin Zhang, Email: bin.zhang@mssm.edu.

Jianji Pan, Email: panjianji1956@163.com.

Reference

  • 1.Lin, et al. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways. J Exp Clin Cancer Res. 2018;37(283). 10.1186/s13046-018-0953-6. [DOI] [PMC free article] [PubMed]

Articles from Journal of Experimental & Clinical Cancer Research : CR are provided here courtesy of BMC

RESOURCES